​

ESSA Pharma Stock (NASDAQ:EPIX)

ForecastOwnershipFinancialsChart
ESSA Pharma by TradingView

Previous Close

$0.20

52W Range

$0.18 - $6.45

50D Avg

$0.83

200D Avg

$1.49

Market Cap

$9.52M

Avg Vol (3M)

$6.75M

Beta

1.53

Div Yield

$1.69 (840.47%)

EPIX Company Profile

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

35

IPO Date

Mar 13, 2015

Website

EPIX Performance

EPIX Financial Summary

Sep 23Sep 22Sep 21
Revenue---
Operating Income$-32.13M$-35.34M$-36.91M
Net Income$-26.58M$-35.10M$-36.81M
EBITDA$-26.46M$-35.08M$-36.71M
Basic EPS$-0.60$-0.80$-0.96
Diluted EPS$-0.60$-0.80$-0.96

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 08Sep 23, 08 | 10:00 AM
Q4 07Feb 25, 08 | 10:00 AM

Peer Comparison

TickerCompany
RADXRadiopharm Theranostics Limited
HCWBHCW Biologics Inc.
ERNAErnexa Therapeutics Inc.
KALAKALA BIO, Inc.
APVOAptevo Therapeutics Inc.
INABIN8bio, Inc.
KPRXKiora Pharmaceuticals, Inc.
APREAprea Therapeutics, Inc.
BCDABioCardia, Inc.